

Post-COVID-19 Cerebral Pheohyphomycosis due to *Rhinoctadiella mackenziei*: A Middle Eastern Replica of Post-COVID-19 Mucormycosis?

Dear Editor,

Healthcare-associated infections (HAIs) are not uncommon after COVID-19. Kubin *et al.* reported that the incidence of post-COVID-19 HAIs was around 12%.^[1] Out of these, 57% were bacterial and 19% were fungal.^[2] Although candidemia was the most common fungal infection, the Indian population witnessed the storm of “mucormycosis.”^[2] The risk factors and the pathophysiology of post-COVID-19 mucormycosis are well described in medical literature.^[2] Recently, we came across a case of “cerebral pheohyphomycosis (CH)” after COVID-19.

Our patient was a 53-year-old female of Arabic ethnicity. She was morbidly obese and had multiple comorbidities. Two months before the present clinical encounter, she was admitted to our hospital with severe COVID-19. She was successfully treated with favipiravir, tocilizumab, and methylprednisolone. After about 1 month, she presented to us with clinicoradiological features of organizing pneumonia. We started a steroid (prednisolone) treatment for her. After 15 days, she reported with facial palsy and left hemiparesis. Neuroimaging was suggestive of right frontal abscess [Figure 1]. She was operated by a neurosurgeon; decompressive craniectomy and debridement of necrotic tissue were done. Brown-colored pus was removed, and pus on macroscopic examination revealed many groups of branching filaments (fungus). We started her on a dual antifungal (liposomal amphotericin-B and caspofungin). Later, the pus on culture revealed the fungus “*Rhinoctadiella mackenziei* (RM),” so the dual antifungal was continued for 2 weeks. This was followed by oral voriconazole for another 2 weeks. We followed her progress for 6 months. She is in stable condition and cured of post-COVID-19 sequelae.

CH is a fungal infection of the brain caused by environmental dematiaceous fungi belonging to the order *Chaetothyriales*.^[3,4] It is a rare opportunistic infection with mortality rate close to 100%.^[3,4] Three species of *Chaetothyriales* order namely *Cladophialophora bantiana*, *Exophiala dermatitidis*, and RM are highly neurotropic and mostly responsible for CH.^[3,4] CH due to RM is restricted to the Middle East with most of the cases reported in Saudi Arabia.^[3,4] The dry and hot climate is said to be responsible for this endemicity.^[3,4] CH due to RM is common in immunocompromised hosts. Around 35% of the cases were reported in immunocompetent patients.^[3,4] Cerebral infection is usually secondary to pulmonary infection.^[3,4] The clinical feature and differential diagnosis of CH are comparable to that of intracranial space-occupying lesions.




Figure 1: Magnetic resonance imaging of brain (T1 with contrast) showing right frontal abscess with the enhancing rim

Magnetic resonance imaging brain with contrast is the investigation of choice that shows ring-enhancing lesions.^[3,4] The definitive diagnosis requires isolation and identification of the fungus from tissue or body fluids by culture. In culture, fungus typically forms slow-growing, pigmented colonies.^[3,4] Treatment consists of surgery and antifungal therapy.^[3,4] Complete excision of abscess is recommended whenever feasible.^[3,4] The combination of antifungal drugs for prolonged duration is recommended.^[3,4]

In our patient, the morbid elements that were observed in the pathophysiology of post-COVID-19 mucormycosis might have played a role in the development of CH. Laiq *et al.* from Oman also reported a case of post-COVID-19 CH.^[5] Such a case raises the question of whether post-COVID-19 CH is a Middle Eastern replica of post-COVID-19 mucormycosis, which has comparable agent, host, and environmental factors. Therefore, we emphasize more observation, reporting, and study of such cases.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that her name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Research quality and ethics statement

The authors followed applicable EQUATOR Network (<http://>

www.equator-network.org/) guidelines, notably the CARE guideline, during the conduct of this report.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Bhushan Sudhakar Wankhade, Ammar Mohamed Abdel Hadi, Ghaya Zeyad Alrais¹, Zeyad Faour Alrais, Ahmad Elzayyat
Department of Surgical Intensive Care, Rashid Hospital, Oud Metha,
¹Dubai Medical College, Dubai, UAE

Address for correspondence: Dr. Bhushan Sudhakar Wankhade,
Department of Surgical Intensive Care Unit, Rashid Hospital, PO Box 4545, Oud
Metha, Dubai, UAE.
E-mail: bhushansudhakar2018@gmail.com

REFERENCES

1. Kubin CJ, McConville TH, Dietz D, Zucker J, May M, Nelson B, *et al.* Characterization of bacterial and fungal infections in hospitalized patients with COVID-19 and factors associated with healthcare-associated infections. *Open Forum Infect Dis* 2021;8:ofab201.
2. Sannathimmappa MB, Nambiar V, Aravindakshan R. Storm of a rare opportunistic life threatening mucormycosis among post COVID-19 patients: A tale of two pathogens. *Int J Crit Illn Inj Sci* 2022;12:38-46.
3. Mohammadi R, Mohammadi A, Ashtari F, Khorvash F, Hakamifard A, Vaezi A, *et al.* Cerebral phaeohyphomycosis due to *Rhinoctadiella mackenziei* in Persian Gulf region: A case and review. *Mycoses* 2018;61:261-5.
4. Yusupov N, Merve A, Warrell CE, Johnson E, Curtis C, Samandouras G. Multiple brain abscesses caused by *Rhinoctadiella mackenziei* in an immunocompetent patient: A case report and literature review. *Acta Neurochir (Wien)* 2017;159:1757-63.
5. Laiq S, Al Yaqoobi M, Al Saadi M, Rizvi S, Al Hajri Z, Al Azri S, *et al.* *Fonsecaea* associated cerebral phaeohyphomycosis in a post-COVID-19 patient: A first case report. *Clin Infect Pract* 2022;13:100126.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code: 	Website: www.jgid.org
	DOI: 10.4103/jgid.jgid_105_22

How to cite this article: Wankhade BS, Abdel Hadi AM, Alrais GZ, Alrais ZF, Elzayyat A. Post-COVID-19 cerebral phaeohyphomycosis due to *Rhinoctadiella mackenziei*: A Middle Eastern replica of Post-COVID-19 mucormycosis? *J Global Infect Dis* 2022;14:173-4.

Received: 03 June 2022 **Revised:** 13 June 2022
Accepted: 21 June 2022 **Published:** 01 November 2022

© 2022 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow